Are You Prescribing Monoclonal Antibodies for COVID-19?

February 03, 2021

In November, the US Food and Drug Administration authorized the use of two monoclonal antibody products, bamlanivimab (Lilly) and casirivimab/imdevimab (Regeneron), to treat outpatients with COVID-19 who are at high risk for complications or hospitalization.

The US government has allocated more than 641,000 monoclonal antibody treatments to the states in the hope of preventing hospitalizations and easing pressure on strained hospitals. However, federal officials reported in January that more than half of that reserve sits unused as clinicians grapple with best practices.

Tell us your thoughts about treating COVID-19 patients with monoclonal antibodies.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.